Drug intelligence / Profile preview

glycoprotein D

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular, Subcutaneous
01

Overview

Glycoprotein D is a **viral envelope protein** found on the surface of herpes simplex viruses (HSV-1 and HSV-2). It is an essential mediator of **viral entry** into host cells by binding to specific host cell surface receptors including **nectin-1, nectin-2, and herpesvirus entry mediator (HVEM)**. This interaction triggers membrane fusion and allows the virus to infect the cell. Glycoprotein D is also a principal target for vaccine development because antibodies against it can neutralize the virus. Subunit vaccines using recombinant or synthetic forms of glycoprotein D have been evaluated but have exhibited limited clinical success in humans. In addition to vaccine strategies, glycoprotein D has been explored as a component to improve immunogenicity of other vaccines (e.g., acting as a local checkpoint inhibitor for T-cell activation in fusion constructs)[1][2][3][5][6][7][8].

Other names
HSV glycoprotein Dherpes simplex virus glycoprotein Dglycoprotein D of HSVgD-1gD1gD 1gD-2gD2gD 2
02

Targets

HS (Heparan sulfate)TNFRSF14 (Tumor necrosis factor receptor superfamily member 14)NECTIN1 (Poliovirus receptor-related 1)NECTIN2 (Nectin cell adhesion molecule 2)BTLA

Beyond the preview

Go deeper on glycoprotein D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on glycoprotein D.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call